Binding was compared against immunohistochemistry, and based on more than 25-fold greater binding to tissue sections with high tau burden relative to amyloid-β, [F-18]-T807 was selected; the first set of images and quantitative binding data of [F-18]-T807 to specific brain regions in a small group of patients with AD and normal controls was very encouraging [159]. This evidence concerns the gene MAPT and Alzheimer disease.